Konstantinos specializes in oligonucleotide therapy development with expertise in disorders of gene regulation. With more than 15 years of research experience across the U.S. and Europe, his work has progressed therapeutic approaches for lysosomal storage and hematopoietic diseases. His passion for rare disease drives his commitment to developing innovative genetic medicines that bring hope to patients and families.
Konstantinos received his B.S. in Biology from Aristotle University of Thessaloniki followed by a master of science in molecular medicine from Imperial College of London. Konstantinos studied nitric oxide signaling in cardiac development for his doctoral work at the Imperial College of London. Following a research fellowship at Harvard University and post-doctoral work at Imperial College of London focused on stem cell therapeutics, Konstantinos worked at MiNA Therapeutics as a Senior Research Scientist responsible for designing and managing preclinical studies for oligonucleotide therapeutics before joining JAX.